FDA to Host Public Meeting on Oversight of Laboratory-Developed Tests
The FDA has announced plans to hold a public meeting on July 19 to 20 to discuss how the agency will oversee laboratory-developed tests (LDTs).
Read MorePosted by Clinical Lab Products | Jun 18, 2010 | Miscellaneous |
The FDA has announced plans to hold a public meeting on July 19 to 20 to discuss how the agency will oversee laboratory-developed tests (LDTs).
Read MorePosted by Clinical Lab Products | Jun 14, 2010 | Cancer, Miscellaneous |
Response Genetics Inc, a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced the addition of Michael B. McNulty as the Companys chief operating officer.
Read MorePosted by Clinical Lab Products | Jun 11, 2010 | Cancer, Miscellaneous |
Clarient Inc announces a new contractual agreement with Generation Health Inc (GH) making Clarient a preferred genetic testing lab for GH.
Read MorePosted by Clinical Lab Products | Jun 10, 2010 | Miscellaneous |
The May issue of the journal Pediatric and Developmental Pathology reports results from a study, which examined the feasibility of CGH and FISH in retrospective genetic analysis to detect chromosomal abnormalities.
Read MorePosted by Clinical Lab Products | Jun 9, 2010 | Cancer, Miscellaneous |
Researchers believe that genetics and traditional screening methods could play a role in predicting the risk of prostate cancer in younger men.
Read More